Introduction
Observational and clinical trial data have accrued to show that acute/chronic heart disease can directly contribute to and/or accelerate acute/chronic worsening kidney function and vice versa. A description of the epidemiology of heart-kidney interaction, as defined by the proposed consensus cardio-renal syndrome (CRS) definitions, is a critical initial step towards understanding not only the overall burden of disease for each of the proposed CRS subtypes, but also their natural history, associated morbidity and mortality and potential health resource implications [1] . Importantly, these CRS subtypes may have important discriminating features in terms of predisposing or precipitating events, risk identification, natural history and outcomes. Likewise, a surveillance of the epidemiology is vital for determining whether there exist important gaps in knowledge and for the design of future epidemiologic investigations and clinical trials. Accordingly, this article will summarize the epidemiology of CRS. HF, heart failure; LVEF, left ventricular ejection fraction; ESC, European Society of Cardiology; AHA, Alberta Heart Association; ACC, American College of Cardiology; TIA, transient ischaemic attack; SCr, serum creatinine; GFR, glomerular filtration rate. function. The spectrum of acute cardiac events that may contribute to AKI and the development of acute cardio-renal syndrome (Type 1 CRS) include acute decompensated heart failure (ADHF), acute coronary syndrome (ACS), cardiogenic shock and cardiac surgery-associated low cardiac output syndrome. There is a large body of literature that has examined AKI attributable to acute worsening of heart function, in particular for ADHF and ACS (Tables 2 and 3) . Most are retrospective, secondary and/or post hoc analyses from large databases [2] [3] [4] [5] [6] [7] [8] or clinical trials of drug therapy [9, 10] . Few were prospective [11] [12] [13] [14] [15] .
The term 'worsening renal function' (WRF) has been regularly used to describe the acute and/or sub-acute changes that occur to kidney function following ADHF or ACS (Table 1 ). The incidence estimates for WRF associated with ADHF and ACS have ranged between 24-45 and 9-19%, respectively. A small single-centre study found that AKI occurred in 48% of paediatric patients admitted for ADHF [16] . The broad range in reported incidence is largely attributable to variations in the definitions of WRF, differences in the observed time-at-risk and the heterogeneity of selected populations being studied (Table 1) .
Many studies used variable durations of observed timeat-risk for ascertainment of WRF. Most commonly, criteria for WRF were fulfilled if the defined changes to kidney function occurred within hospital admission [4, 5, 15] . This is problematic when considering the variation in duration of hospital stay both between individual patient admissions and between studies. Other studies observed for WRF for 2 weeks [9] and up to 6 months [17] . These variations in observed time-at-risk for WRF have the potential to introduce bias and misclassification. In ADHF, Gottlieb et al. showed that 47% had WRF within 3 days of hospital admission [4] , while Cowie et al. found that 50% occurred within 4 days [11] . Both Cowie et al. and Krumholz et al. showed that 70-90% of all WRF had occurred within the first week of hospital admission [5, 11] . Likewise, two studies have shown that the time to peak change in serum creatinine (SCr) had occurred within 5 days of hospital admission [13, 14] . Goldberg et al. found that 75% of AKI occurring in association with ACS occurred within 3 days after hospital admission [3] . Accordingly, these differences in time to ascertain WRF/AKI will influence the incidence and outcome estimates and unduly influence the generalizability and inference from any given study.
Several clinical factors have been shown to be associated with increased risk for WRF including male sex, kidney dysfunction at the time of hospital admission, worsened heart failure (HF) (i.e. NHYA class, left ventricular ejection fraction or pulmonary oedema), tachyarrhythmias and elevated blood pressure at hospital admission. Similarly, several therapy-related factors have shown association with WRF including high-dose diuretic and/or vasodilator therapy [2, 5, 10, 11, 14, 18] .
In both ADHF and acute myocardial infarction (AMI), the development of WRF/AKI has been associated with worse clinical outcomes and higher health care costs [5] ( Tables 2 and 3 ). In ADHF, the presence of AKI confers an increased risk for both short-term and long-term all- cause and cardiovascular mortality [2, 4, 5, 10, 11, [13] [14] [15] .
Moreover, there appears to be a biological gradient seen between severity of AKI and risk of death [15] . Two studies have shown that the risk of poor outcome persisted regardless of whether WRF/AKI was transient or sustained [12, 13] . Several studies have shown that the development of AKI in association with ADHF prolongs stay in hospital [4, 5, 11, 13, 14] . While two studies showed that AKI in ADHF was associated with increased readmission rates [13, 14] , this was not a universal finding [5, 10, 11, 15] . Similar to ADHF, AKI associated with ACS appears to significantly modify the risk of poor outcome [3, [7] [8] [9] 12] . Importantly, even small acute changes in SCr appear to modify the risk of death [9] . In addition, data have also suggested a greater occurrence of cardiovascular events such as congestive heart failure (CHF), recurrent ACS and stroke and need for re-hospitalization among patients who developed AKI [9] . Newsome et al. reported a greater likelihood and/or rate of progression to end-stage kidney disease (ESKD) in those with ACS complicated by AKI [7] . These data would suggest that the development of AKI in association with ADHF or ACS may further exacerbate cardiac injury and/or function and also contribute to exaggerated declines in kidney function. This would imply that the observed heart-kidney interface in Type 1 CRS may synergistically act to further accelerate injury and/or dysfunction following the initial insult.
Recommendations for clinical practice. We suggest the use of an established consensus definition/classification for AKI in clinical practice and future studies enrolling ADHF/ACS patients. We also favour the use of the term AKI rather than WRF. The term AKI better represents the entire spectrum of acute renal failure and would enable integration of Type 1 CRS into the broader context of AKI. We believe there is a need to define a relevant time frame for ascertainment of AKI associated with ADHF and/or ACS. The ideal 'ascertainment time' would identify AKI as being most likely attributable to the acute cardiac event rather than due to observed complications of therapy or more chronic processes (where prognosis may differ). We suggest that the diagnosis of AKI in association with ADHF/ACS should be determined within the first 7 days of hospitalization based on data showing that the majority of patients (>90%) would be captured within this time frame. This would permit greater standardization of data across future epidemiologic investigations.
Recommendations for future research. Future investigations should evaluate the incidence, temporal profile and outcomes of Type 1 CRS in selected populations (i.e. ADHF, ACS) with the use of established consensus definitions for AKI. Clinical outcomes should include both short-term and long-term mortality along with major morbidity outcomes (i.e. kidney function, progression to ESKD, cardiovascular events, quality of life, health care costs). We also recognize that the current definition for Type 1 CRS only explicitly considers establishing the diagnosis and presence of pathologic heart-kidney interaction. However, there is also the need to acknowledge that, once present, this interaction may synergistically compound existing and/or further accelerate bi-directional injury and/or dysfunction in either organ system. We believe that this requires investigation to better understand the pathophysiology and natural history of patients diagnosed with Type 1 CRS.
Chronic cardio-renal syndrome
This syndrome is characterized by chronic abnormalities in cardiac function leading to kidney injury or dysfunction. This subtype indicates a more chronic state of kidney disease complicating chronic heart disease. The term 'chronic cardiac abnormalities' encompasses several different conditions including chronic HF, atrial fibrillation, congenital heart disease, constrictive pericarditis and chronic ischaemic heart disease ( Table 4) . Chronic heart disease and chronic kidney disease (CKD) frequently co-exist. The clinical circumstances often present a challenge for determining which disease process was primary versus secondary. This challenge is likewise evident when appraising the literature and applying the proposed consensus CRS subtype definitions in a retrospective manner. Several large database studies have assembled patient cohorts based on the presence of one disease (i.e. CHF) while estimating the prevalence/incidence of the other (i.e. kidney dysfunction). For example, in the ADHERE study, evaluating 118 465 ADHF admissions, 27.4, 43.5 and 13.1% of patients were found to have mild, moderate and severe kidney dysfunction at the time of hospital admission, respectively [19] . Increasing severity of dysfunction was found to portend worse clinical outcomes, including ICU admission, mechanical ventilation, length of stay and inhospital mortality. Similarly, in a secondary analysis of the Digitalis Investigation Group trial, Campbell et al. found that CKD in ambulatory patients with chronic HF (45% of cohort) was associated with increased risk of hospitalization and death [20] . Moreover, there was a biologic gradient in the risk for hospitalization and mortality as glomerular filtration rate (GFR) decreased. These data clearly highlight the common co-existence of heart and kidney dysfunction and associated poor prognosis; however, very few studies are able to clearly separate the occurrence of kidney disease in time from the occurrence of heart disease. Therefore, the current body of literature does not readily allow for clear discrimination between chronic cardio-renal syndrome (Type 2 CRS) and chronic reno-cardiac syndrome (Type 4) CRS (see below).
A recent pooled analysis of data from the Atherosclerosis Risk in Communities Study and Cardiovascular Health Study provided further insight into the epidemiology of Type 2 CRS [21] . Patients with baseline cardiovascular disease (CVD) constituted 12.9% of the study population. These patients had a mean baseline SCr 79.6 µmol/L [0.9 mg/dL] and estimated glomerular filtration rate (eGFR) 86.2 mL/min/1.73 m 2 . After a mean follow-up of 9.3 years, 7.2% of CVD patients had declines in kidney function when defined as a SCr increase of ≥35.4 µmol/L [0.4 mg/dL] and 34% when defined as a decrease in eGFR ≥ 15 mL/min/ 1.73 m 2 . During the observational period, 2.3% and 5.6% developed new kidney disease, respectively. By multi-variable analysis, baseline CVD was independently associated with both decline in kidney function and development of new CKD. These data provide compelling evidence for the attributable risk of CVD for declines in kidney function (OR 1.70, 95% CI 1.36-2.31) and CKD (OR 1.75, 95% CI 1.32-2.32) and the concept of Type II CRS.
'Cyanotic nephropathy' has long been recognized as a potential complication of cyanotic congenital heart disease [22, 23] . Infants born with congenital heart defect, in the majority of circumstances, have normal kidneys. Dimopoulos et al. studied 1102 patients (mean age 36 years) surviving into adulthood with congenital heart disease [24] . Amongst this cohort, >50% had evidence of kidney dysfunction that was considered mild (eGFR 60 to 89 mL/min per 1.73 m 2 ) in 41% and moderate-severe (eGFR < 60 mL/min per 1.73 m 2 ) in 9%. Patients with Eisenmenger physiology had the lowest eGFR and the highest prevalence of moderate or severe reduced GFR (18%). Similarly, there was a trend towards greater kidney dysfunction in patients with more complex anatomy. However, kidney dysfunction was detected even among patients characterized as having 'simple' defects. Importantly, kidney dysfunction had a substantial impact on mortality (propensity score-weighted HR 3.25, P = 0.002 for impaired versus normal GFR).
Recommendations for clinical practice. We suggest classification of patients into CRS subtypes based on the initial diagnosis of either CKD or CVD. For example, when CVD clearly precedes onset of CKD, as in congenital heart disease, patients should be classified as Type 2 CRS. We recognize that clear discrimination of the primary versus secondary process will not always be possible given the prevalence of co-existing CVD and CKD. In these circumstances, we recommend patients be classified as having both (i.e. Type 2/4 CRS).
Recommendations for future research. Future clinical studies need to prospectively evaluate the incidence and timing of de novo kidney dysfunction, stratified by CVD type (i.e. CHF, IHD, congenital heart disease) and severity. The rate of progression of pre-existing CKD in patients with established CVD and whether synergistic interaction occurs also deserve more precise quantification, as well as the effect of cardio-protective therapies on these renal endpoints. With the proposed consensus definitions, it would now be possible to characterize transition between different CRS types. As aforementioned, we believe investigations should be performed for risk identification of potential unique subsets of patients with Type 2 CRS who may exhibit accelerated kidney injury and/or dysfunction in the context of chronic CVD. Such studies should incorporate kidney-and cardiac-specific biomarkers to further establish the mechanistic link of heart-kidney interaction. The negative effects of combined chronic heart disease and CKD on mortality and cardiovascular events are well-recognized; other long-term clinically relevant endpoints should include health-related quality of life and health care costs.
Acute reno-cardiac syndrome
This syndrome is characterized by acute worsening of kidney function (i.e. AKI) that leads to acute cardiac injury and/ or dysfunction (i.e. AMI, CHF, arrhythmias). Selected prototypical conditions contributing to acute reno-cardiac 1410 S.M. Bagshaw et al.
syndrome (Type 3 CRS) would include contrast-induced acute kidney injury (CI-AKI), other drug-induced nephropathies, AKI after major non-cardiac surgery, AKI after cardiac surgery, post-infectious glomerulonephritis, rhabdomyolysis and any additional aetiology for which AKI directly contributes to acute cardiac dysfunction. The association of AKI and acute cardiac dysfunction with these conditions likely share some similar predisposing risks for development and pathophysiologic mechanisms (i.e. volume overload, systemic hypertension, retention of uremic solutes, hyperkalaemia). We also recognize, however, that the mechanisms contributing to Type 3 CRS likely extend beyond simply retention of uremic solutes and/or volume overload. Similar to prior CRS subtypes, defining the epidemiology of Type 3 CRS is challenging for several reasons: (i) considerable heterogeneity in predisposing conditions causing AKI, (ii) different methods for defining AKI, (iii) variable baseline risk in individuals for the development of acute cardiac dysfunction (i.e. increased susceptibility in individuals with sub-clinical CVD) and (iv) failure of many clinical studies of AKI to report the occurrence of acute cardiac dysfunction as outcomes. Accordingly, incidence estimates and associated clinical outcomes of acute cardiac dysfunction following the development of AKI are largely contextspecific and disease-specific.
As an example, CI-AKI remains a leading cause of iatrogenic kidney injury following diagnostic and interventional procedures and portends adverse effects on prognosis, progression of CKD and consumption of health resources [25] . While AKI is most often attributable to the administration of contrast media, additional confounding factors (i.e. atheroembolic disease, kidney hypoperfusion, concomitant nephrotoxins) may also be contributory. The reported incidence is highly variable depending on the population-at-risk being evaluated [i.e. age, CKD, diabetes mellitus (DM), HF] and the type of procedure performed (i.e. emergent, intra-vascular, type and volume of contrast media). Incidence estimates have been reported in the range of 1-40% [25] [26] [27] . Moreover, the incidence of CI-AKI will likely increase with the broader utilization of contrast media for various procedures along with increasing prevalence of both CKD and DM. The natural history of CI-AKI in many patients may follow an asymptomatic rise in SCr with early return to baseline and these patients would not be expected to fulfil the criteria for Type 3 CRS. However, in an estimated 0.2-1.1%, AKI progresses to require the initiation of renal replacement therapy (RRT) [25, 26, 28] . In these patients, AKI may be associated with volume overload, retention of uremic solutes, CHF, pulmonary oedema and cardiac arrhythmias. Importantly, those at risk for developing CI-AKI requiring RRT may be identifiable a priori. Several factors have been found to independently predict requirement for RRT after contrast media including older age, pre-existing CKD, DM, CVD, HF and volume/dose of contrast media [25] . However, the difficulty in evaluating the epidemiology of Type 3 CRS attributable to CI-AKI is that few studies have specifically reported the temporal occurrence of cardiovascular events following contrast media exposure [29] .
Recommendations for clinical practice. There are no specific recommendations for clinical practice in this area.
Recommendations for future research. Incorporate published/validated consensus definitions for AKI in future epidemiologic studies. We believe the incorporation of cardiovascular events as outcomes is needed to better understand and characterize the epidemiology of Type 3 CRS. To conduct primary investigations to characterize factors associated with those at risk or those susceptible for acute cardiac dysfunction in AKI and determine whether these factors may be preventable and/or modifiable.
Chronic reno-cardiac syndrome
The Type 4 CRS is a condition where primary CKD contributes to a reduction in cardiac function (i.e. cardiac remodelling, left ventricular diastolic dysfunction, left ventricular hypertrophy) and/or an increased risk for cardiovascular events (i.e. myocardial infarction, HF, stroke). This CRS subtype refers to cardiac dysfunction and/or disease primarily occurring in response to CKD. CKD is generally classified into five clinical stages based on changes to GFR and kidney damage [30] .
Several observational studies have evaluated the cardiovascular event rates and outcomes in selected CKD-specific populations [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . Most were retrospective and/or secondary/post hoc analyses from large clinical databases or randomized clinical trials. Despite this abundance of data, the precise epidemiology of Type 4 CRS is similarly challenging to summarize and estimates vary due largely to differences in the populations-at-risk studied, in the clinical outcomes evaluated, in the duration of time for ascertainment of study endpoints and in the operational definitions used for CKD, cardiac disease and mortality (i.e. all-cause or CVD-specific) ( Table 5) .
For example, the populations-at-risk in these studies, based on the presence and/or severity of CKD, ranged from near-normal kidney function to ESKD. Cheung et al., in a secondary analysis of the multi-centre Hemodialysis (HEMO) Study, found that 80% of ESKD patients enrolled in the trial had some form of cardiac disease at baseline [31] . Older patients, diabetics and those who have been receiving a longer duration of maintenance RRT (>3.7 years) had higher prevalence of cardiac disease. During follow-up, 39.8% of enrolled patients were admitted to hospital for cardiac-related diagnoses. Of these, 42.7% were attributable to ischaemic CHD. Of the 39.4% of cardiac deaths, 61.5% were attributable to ischaemic CHD. Baseline cardiac disease in this cohort was significantly predictive of cardiac-specific death during follow-up (relative risk 2.57). Cardiac disease in ESKD patients is exceedingly common, and cardiac-specific mortality rates are 10-20-fold higher when compared with age-and sex-matched non-CKD populations [44] . Moreover, recent data have emerged to suggest dialysis prescription in selected patients with ESKD receiving chronic maintenance dialysis may precipitate cardiac injury and contribute to accelerated declines in myocardial performance [45, 46] .
In those CKD patients not receiving maintenance RRT, the prevalence of CVD varies considerably with CKD severity (and hence time-at-risk) [40] [41] [42] . The risks of CVD events and death is also likely modified further by older age, additional comorbidities and presence of concomitant CHF [37, 41, 42] . In data from the NHANES II study, Munter et al. found a CVD prevalence of 4.5, 7.9 and 12.9% for patients with eGFR ≥90, 70-89 and <70 mL/min/cm 2 , respectively [43] . Likewise, in a large population-based cohort, Go et al. found similar graded increases in the prevalence of CVD and HF, along with higher risk of subsequent cardiac events during follow-up associated with the ESKD, end-stage kidney disease; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; CHF, congestive heart failure; CVD, cerebrovascular disease; MA, microalbuminuria; CHD, coronary heart disease; LVH, left ventricular hypertrophy; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ADHF, acute decompensated heart failure.
degree of decline in eGFR < 60 mL/min/1.73 cm 2 [35] . This dose-response trend in CVD prevalence by severity of CKD also translated into similar trends for risk of cardiac-specific and all-cause mortality [31, 35, [38] [39] [40] 43] .
Several investigations now conclude that the presence of CKD accelerates the risk for and development of CVD [34, 41, 42] . This accelerated risk for cardiovascular events and disease in patients with CKD may be the consequence of unique pathophysiology that exists in these patients [47] . These CKD patients may represent a unique subset with identifiable clinical features.
In addition to a high prevalence of conventional cardiovascular risk factors, the elevated CVD risk may also involve a complex sets of processes not completely understood including hyper-homocysteinaemia, elevated lipoprotein (a), oxidative stress, endothelial dysfunction, chronic inflammation, vascular remodelling [48] , alterations in platelet aggregation, neurohormonal activation, volume overload, reduced parenchymal mass and hormone deficiencies [47] . In broader epidemiologic terms, the exaggerated risk or worsening of CVD in CKD patients may also be explained by additional factors. First, current data from observational studies or secondary analyses may fail to account for residual or uncontrolled confounding. Second, CKD patients have traditionally been excluded from numerous therapeutic clinical trials [49] , and perhaps as a consequence, receive less or sub-optimal risk-modifying and cardio-protective therapies [50] . Finally, the concern for treatment toxicities, intolerance and/or risks in CKD patients or WRF may be such that therapy is not offered due to perception of a less favourable risk-benefit ratio (so-called therapeutic nihilism) [51] . It is plausible that these factors, in part, may provide explanation for the excess of cardiac disease and worse clinical outcomes for CKD patients.
However, large-scale, prospective data on CKD population-specific treatment effects are lacking.
Finally, characterization of the epidemiology of Type 4 CRS from the available literature is difficult, in part, due to inability to clearly discriminate between the primary versus secondary disease process and the considerable overlap that likely exists with Type 2 CRS, as previously discussed. Moreover, we recognize that the current definition for Type 4 CRS only explicitly considers establishing the presence of pathologic heart-kidney interaction and does not explicitly identify and/or incorporate provision for subsets of patients where CKD may act to significantly modify the risk of cardiovascular events and accelerate CVD.
Recommendations for clinical practice. CKD patients with Type 4 CRS have the greatest potential for transition between CRS subtypes. This has the potential to produce uncertainty in how to classify patients (i.e. Type 2 CRS, Type 3 CRS). We suggest that CKD patients should be primarily classified according to their baseline (i.e. pre-hospitalization or pre-event) status with 'transition' to include a second CRS subtype. Likewise, as previously discussed, we recognize that clear discrimination of the primary versus secondary process will not always be possible in these patients given the high prevalence of co-existing CVD and CKD. In these circumstances, we recommend that patients be classified as having both (i.e. Type 2/4 CRS).
Recommendations for future research. Future clinical studies need to evaluate the prevalence of CVD and the incidence of CVD events stratified by CKD severity, examine the temporal profile/change to both kidney and cardiac function over time and incorporate kidney-and cardiacspecific biomarkers to further establish the mechanistic link of kidney-heart interaction in these patients. Likewise, clinical studies are needed to investigate the incidence of and risk factors for accelerated CVD in patients with CKD. We recognize that such patients may require unique identification in further revised definition for Type 1 CRS and other CRS subgroups. In addition, future clinical trials and phase IV observational studies need to evaluate the impact and tolerance of CKD patient-specific risk-modifying and/or cardio-protective therapies.
Secondary cardio-renal syndromes
This syndrome is characterized by acute or chronic systemic illnesses that concurrently induces both cardiac and kidney dysfunction. There is limited data on the epidemiology of secondary cardio-renal syndromes (Type 5 CRS) in general due to the large number of potential contributing acute and chronic systemic conditions. Accordingly, estimates of incidence, risk identification and associated outcomes for Type 5 CRS are largely considered disease-and/or context-specific and may be time-varying. Importantly, there is currently an incomplete understanding of the pathophysiologic mechanisms of secondary cardiackidney interaction. Specifically, whether concomitant cardiac and kidney dysfunction in systemic illness is merely co-existent or whether there is genuine bi-directional interaction that may directly contribute to aggravated dysfunc- tion in either organ system (i.e. additive and/or synergistic). Moreover, there is a lack of data to support when the onset of such bi-directional cardiac-kidney interaction occurs that would fulfil the criteria for a secondary CRS. We have summarized selected potential acute and chronic systemic conditions that may contribute to Type 5 CRS in Table 6 .
The prototypical condition that may lead to acute Type 5 CRS is sepsis. Sepsis occurs at a rate of three cases per 1000 population and is increasing by an estimated 8.7%/year [52, 53] . The case fatality remains high and estimated to be between 20 and 60%, a rate comparable to the annual mortality for AMI [52, 53] . While data have suggested a declining trend in mortality, the absolute number of patients dying from sepsis has increased [52] [53] [54] [55] . Approximately 11-64% of septic patients develop AKI [56] [57] [58] [59] [60] and 46-58% have sepsis as a major contributing factor to the development of AKI [61, 62] . Numerous studies have shown higher morbidity and mortality for those with septic AKI when compared to those with either sepsis or AKI alone [56, 58, [60] [61] [62] . Similarly, abnormalities in cardiac function are common in critically ill patients with sepsis [63] [64] [65] . The incidence of cardiac dysfunction in sepsis is conditional on the population-at-risk being studied, the definition used for the detection of cardiac dysfunction (i.e. troponin elevation, B-type natriuretic peptide, low cardiac output by pulmonary artery catheter, left ventricular dysfunction by echocardiography), severity of illness, resuscitation and duration of illness prior to evaluation. However, observational data have found that approximately 30-80% have elevated cardiac-specific troponins [66] [67] [68] [69] that often correlate with reduced cardiac function [64, [68] [69] [70] . Acute kidney and myocardial dysfunction in sepsis are accordingly common, yet there is a lack of integrative and epidemiologic studies that have specifically examined for insight on the pathophysiology, incidence, risk identification and associated outcomes for septic patients with concomitant AKI and myocardial depression who may fulfill the criteria for acute Type 5 CRS.
Recommendations for future research. For Type 5 CRS, studies are needed to characterize and recognize the spectrum of acute/chronic systemic illnesses that simultaneously lead to acute/chronic pathologic heart-kidney interaction. Both experimental and epidemiologic investigations of systemic illnesses can be conducted to evaluate the impact on and temporal changes in both heart and kidney function occurring in response to co-existent acute/ chronic heart and kidney injury/dysfunction and to determine whether screening/monitoring can be performed.
Conclusions
Kidney and cardiac disease are increasingly encountered and frequently co-exist. A large body of accumulated observational and clinical trial data has found that acute/chronic cardiac disease can directly contribute to acute/chronic worsening kidney function and vice versa. The proposed CRS subtypes (1 to 5) are all characterized by important heart-kidney interactions that likely share some similarities in pathophysiology; however, all appear to have important discriminating features in terms of predisposing or precipitating events, risk identification, natural history and outcomes. Type 1 CRS is common, with incidence estimates of AKI in ADHF or ACS between 24-45 and 9-19%, respectively. Important, the development of Type 1 CRS clearly translates into higher morbidity and worse clinical outcome. Chronic heart disease and CKD are increasing in prevalence and frequently co-exist. Accordingly, this presents challenges for applying the proposed definitions for Type 2 and 4 CRS to the existing literature 'in retrospect' when the primary versus secondary process cannot be clearly discriminated. Due to heterogeneity, the incidence and outcome estimates associated with Type 3 CRS are largely context-specific and disease-specific. Limited data is available on the epidemiology or the pathophysiologic mechanisms of secondary heart-kidney interaction (Type 5 CRS) due to the large number of potential contributing conditions. Accordingly, the epidemiology of Type 5 CRS is largely disease-specific and context-specific. In summary, there is a clear need for additional prospective studies to characterize the epidemiology of heart-kidney interactions across the CRS subtypes, not only for a better understanding of the overall burden of disease, but also for risk identification and identification of potential targets for therapeutic intervention or modification in future investigations.
